{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:41:58Z","timestamp":1791024118796,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3216,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009578","name":"Mizutani Foundation for Glycoscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.bbadis.2004.07.001","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T15:43:53Z","timestamp":1091720633000},"page":"250-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Transgenic mouse expressing human mutant \u03b1-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease"],"prefix":"10.1016","volume":"1690","author":[{"given":"Satoshi","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Mannen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok B.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2004.07.001_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.07.001_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.bbadis.2004.07.001_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0046-8177(90)90258-7","article-title":"Restricted accumulation of globotriaocylceramide in the hearts of atypical cases of Fabry's disease","volume":"21","author":"Ogawa","year":"1990","journal-title":"Human Pathol."},{"key":"10.1016\/j.bbadis.2004.07.001_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.07.001_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.07.001_bib6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.bbadis.2004.07.001_bib7","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2004.07.001_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group, safety and efficacy of recombinant human \u03b1-Galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.07.001_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2004.07.001_bib10","first-page":"1186","article-title":"Nature and frequency of mutations in the \u03b1-Galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2004.07.001_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the \u03b1-Galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2004.07.001_bib12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1006\/bbrc.1996.0486","article-title":"Aggregation of the inactive form of human \u03b1-Galactosidase in the endoplasmic reticulum","volume":"220","author":"Ishii","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2004.07.001_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-Galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2004.07.001_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2004.07.001_bib15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2004.07.001_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-Galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2004.07.001_bib17","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer","volume":"10","author":"Ziegler","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2004.07.001_bib18","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1073\/pnas.120177997","article-title":"Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells","volume":"97","author":"Takenaka","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2004.07.001_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-5793(97)01263-5","article-title":"Generation and characterization of transgenic mice expressing a human mutant \u03b1-Galactosidase with an R301Q substitution causing a variant form of Fabry disease","volume":"417","author":"Shimmoto","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbadis.2004.07.001_bib20","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1074\/jbc.271.25.15109","article-title":"Molecular cloning and genomic analysis of mouse Galb1,3GalNAc-specific GalNAc a2,6-sialyltransferase","volume":"271","author":"Kurosawa","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2004.07.001_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0167-4838(94)90017-5","article-title":"Human \u03b1-Galactosidase gene expression: significance of two peptide regions encoded by exons 1\u20132 and 6","volume":"1204","author":"Ishii","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.07.001_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0304-4165(00)00171-9","article-title":"Characterization of blood group ABO(H)-active gangliosides in type AB erythrocytes and structural analysis of type A-active ganglioside variants in type A human erythrocytes","volume":"1525","author":"Kushi","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.07.001_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1023\/A:1006915926732","article-title":"\u03b1-Galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues","volume":"15","author":"Ishii","year":"1998","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.bbadis.2004.07.001_bib24","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1038\/sj.onc.1202736","article-title":"Heart-specific activation of LTK results in cardiac hypertrophy cardiomyocyte degeneration and gene reprogramming in transgenic mice","volume":"18","author":"Honda","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2004.07.001_bib25","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-Galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904001322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904001322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:35:54Z","timestamp":1760416554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443904001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0925443904001322"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2004.07.001","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transgenic mouse expressing human mutant \u03b1-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2004.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}